| Literature DB >> 22377422 |
Prahlad T Ram1, John Mendelsohn, Gordon B Mills.
Abstract
Delivering personalized therapeutic options to cancer patients based on the genetic and molecular aberrations of the tumor offers great promise to improve the outcomes of cancer therapy. Significant progress in biotechnology has allowed the measurement of tens of thousands of "omic" data points across multiple levels (DNA, RNA protein, metabolomics) from a single tumor biopsy sample in a reasonable time frame for making clinical decisions. With this data in hand, the challenge from the bioinformatics and systems biology point of view is how does one convert data into information and knowledge that can improve the delivery of personalized therapy to the patient.Entities:
Mesh:
Year: 2012 PMID: 22377422 PMCID: PMC3345061 DOI: 10.1016/j.molonc.2012.01.008
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 6.603